國家衛生研究院 NHRI:Item 3990099045/12522
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 913754      線上人數 : 1224
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版
    國家衛生研究院 NHRI > 癌症研究所 > 其他 > 期刊論文 >  Item 3990099045/12522


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12522


    題名: Validation of an EBV antibody risk stratification signature for nasopharyngeal carcinoma using multiplex serology
    作者: Simon, J;Liu, Z;Brenner, N;Yu, KJ;Hsu, WL;Wang, CP;Chien, YC;Coghill, AE;Chen, CJ;Butt, J;Proietti, C;Doolan, DL;Hildesheim, A;Waterboer, T
    貢獻者: National Institute of Cancer Research
    摘要: Introduction: Serological testing for nasopharyngeal carcinoma (NPC) has recently been reinvigorated by the implementation of novel Epstein-Barr virus (EBV) specific IgA and IgG antibodies from a proteome array. Although proteome arrays are well-suited for comprehensive antigen selection, they are not applicable for large-scale studies.Methods: We have adapted a 13-marker EBV antigen signature for NPC risk identified by proteome arrays to multiplex serology, to establish an assay for large-scale studies. Taiwanese NPC cases (n=175) and matched controls (n=175) were used for assay validation. Spearman's correlation was calculated and the diagnostic value of all multiplex markers was assessed independently using the area under the receiver operating characteristic curve (AUC). Two refined signatures were identified using stepwise logistic regression, and internally validated with 10-fold cross validation.Results: Array and multiplex serology showed strong correlation for each individual EBV-marker, as well as for a 13-marker combined model on continuous data. Two refined signatures with either four (LF2 and BGLF2 IgG, LF2 and BMRF1 IgA) or two antibodies (LF2 and BGLF2 IgG) on dichotomous data were identified as the most parsimonious set of serological markers able to distinguish NPC cases from controls with AUCs of 0.992 (95% CI 0.983-1.000) and 0.984 (95% CI 0.971-0.997), respectively. Neither differed significantly from the 13-marker model (AUC = 0.992; 95% CI 0.982-1.000). All models were internally validated.Conclusion: Multiplex serology successfully validated the original EBV proteome microarray data. Two refined signatures of four and two antibodies were capable of detecting NPC with 99.2% and 98.4% accuracy.
    日期: 2020-04-23
    關聯: Journal of Clinical Microbiology. 2020 Apr 23;58(5):Article number e00077-20.
    Link to: http://dx.doi.org/10.1128/jcm.00077-20
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0095-1137&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000535797600002
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85084025047
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB32102852.pdf2252KbAdobe PDF230檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋